Technical Analysis for ETX - E-Therapeutics Plc

Grade Last Price % Change Price Change
F 10.20 3.82% 0.38
ETX closed up 3.82 percent on Wednesday, April 17, 2024, on 7.24 times normal volume.
Earnings due: May 2
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Gapped Up Strength 0.00%
180 Bearish Setup Bearish Swing Setup 3.82%
Calm After Storm Range Contraction 3.82%
Lower Bollinger Band Walk Weakness 3.82%
Multiple of Ten Bearish Other 3.82%

   Recent Intraday Alerts

Alert Time
3x Volume Pace about 13 hours ago
2x Volume Pace about 13 hours ago
1.5x Volume Pace about 13 hours ago
Bearish 180 Entry about 14 hours ago
Fell Below Previous Day's Low about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


E-Therapeutics Plc Description

e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.


Sector: Healthcare
Industry: Biotechnology
Keywords: Health Chemical Hedge Cancer Clinic Nature Biology Oncology Drug Discovery Clinical Trial Resistance Itn Antibiotic Therapies Biocides Pharmacology Cancer Therapies Erase

Is ETX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 24.0
52 Week Low 8.0
Average Volume 599,237
200-Day Moving Average 13.44
50-Day Moving Average 13.09
20-Day Moving Average 11.42
10-Day Moving Average 11.13
Average True Range 1.18
RSI (14) 38.27
ADX 21.53
+DI 15.86
-DI 27.59
Chandelier Exit (Long, 3 ATRs) 9.47
Chandelier Exit (Short, 3 ATRs) 12.73
Upper Bollinger Bands 13.03
Lower Bollinger Band 9.82
Percent B (%b) 0.12
BandWidth 28.14
MACD Line -0.63
MACD Signal Line -0.60
MACD Histogram -0.0299
Fundamentals Value
Market Cap 59.6 Million
Num Shares 584 Million
EPS -0.02
Price-to-Earnings (P/E) Ratio -510.00
Price-to-Sales 262.95
Price-to-Book 3.25
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.88
Resistance 3 (R3) 11.96 11.48 11.60
Resistance 2 (R2) 11.48 11.05 11.44 11.51
Resistance 1 (R1) 10.84 10.79 10.60 10.76 11.41
Pivot Point 10.36 10.36 10.24 10.32 10.36
Support 1 (S1) 9.72 9.93 9.48 9.64 8.99
Support 2 (S2) 9.24 9.67 9.20 8.89
Support 3 (S3) 8.60 9.24 8.80
Support 4 (S4) 8.52